Hyperfine, Inc. (HYPR) company profile
Close on Nov 17, 2026Market cap $59.56MP/E –Yield –
About Hyperfine
Electromedical & Electrotherapeutic Apparatus, SIC 3845
The health technology company develops and commercializes artificial intelligence-powered portable magnetic resonance imaging solutions. Its principal offering is the Swoop Portable MR Imaging System, an ultra-low-field brain scanner integrated with deep learning software designed to deliver neuroimaging directly at the point of care, including bedside hospital settings and outpatient clinics. Operating alongside the scanner hardware, the business provides proprietary software sequences, annual service agreements, and a subscription-based research data platform. The company primarily serves healthcare providers, including critical care units, emergency departments, inpatient hospital facilities, and office-based neurology practices, as well as international clinical providers.
Direct commercial activities occur primarily within the United States, complemented by authorized third-party distributor relationships that serve international healthcare institutions across Canada and select markets in Europe, Asia, Oceania, and the Middle East. Beyond the domestic market, regulatory marketing authorizations and product approvals span Canada, Australia, New Zealand, India, the United Kingdom, and the European Union.
Summary of the business section of Hyperfine's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Hyperfine, Inc.
- Founded
- 2014
- Headquarters
- Guilford, CT
- Address
- 351 New Whitfield Street 06437
- Phone
- (866) 796-6767
- Website
- hyperfine.io
- Employees
- 102, Dec 31, 2025
- Industry
- Electromedical & Electrotherapeutic Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- GRANT THORNTON LLP, San Jose, California
Stock & identifiers
- Ticker
- HYPR
- Former tickers
- HCAQ until Dec 28, 2021
- Exchange
- Nasdaq
- IPO date
- Jan 28, 2021
- Shares outstanding
- 106M, Aug 3, 2026
- Public float
- $44.20M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1833769
- CUSIP
- 44916K106
- ISIN
- US44916K1060
- FIGI
- BBG00YVTN9J2
- Share class FIGI
- BBG00YVTN9K0
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Maria Sainz | President and CEO, Director | 789,586 |
| Brett Hale | CFO and CAO | 592,420 |
| Thomas Teisseyre | Chief Operating Officer | 671,256 |
| Dan Wolterman | Director | 19,586 |
| Ruth A. Fattori | Director | 20,477 |
| Jonathan M. Rothberg | Director | 17,062,534 |
| John T. Dahldorf | Director | 19,586 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Total | vs. prior year |
|---|---|---|---|---|---|
| Maria Sainz President and Chief Executive Officer | $582.23K | – | $314.59K | $896.82K | -60% |
| Brett Hale Chief Administrative Officer and Chief Financial Officer | $449.82K | $214.80K | $135.02K | $799.63K | -24% |
| Thomas Teisseyre Chief Operating Officer | $449.82K | $214.80K | $135.02K | $799.63K | -24% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- Jan 28, 2021
- Offer price
- $10.00
- Exchange
- Nasdaq
- First trading day
- Jan 27, 2021
- First-day close
- $10.01+0.1%
- Lock-up ends (est.)
- Jul 26, 2021
“This is an initial public offering of our Class A ordinary shares, par value $0.0001 per share, which we refer to as our public shares, at an initial public offering price per share of $10.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of February 15, 2026, we had 102 employees, all of whom were full-time employees and of whom 24 work in sales, marketing, and commercial support, 56 work in research, development, clinical, technical assistance, supply chain, operations and logistics and 22 work in general and administrative capacities.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?